Claims
- 1. A composition for the treatment of an anorectal disorder, and for controlling the pain associated therewith, said composition comprising a NO donor in admixture with a second agent selected from the group consisting of phosphodiesterase type II inhibitors, phosphodiesterase type IV inhibitors, phosphodiesterase type V inhibitors, nonspecific phosphodiesterase inhibitors, superoxide scavengers, β-adrenergic agonists, cAMP-dependent protein kinase activators, α1-adrenergic antagonists, estrogens, ATP-sensitive K+ channel activators and smooth muscle relaxants, with a pharmaceutically acceptable carrier.
- 2. A composition in accordance with claim 1, wherein said NO donor is selected from the group consisting of nitroglycerin, L-arginine, SNAP−, GSNO and SIN-1, and said second agent is a superoxide scavenger selected from the group consisting of superoxide dismutase and chemical superoxide dismutase mimetics.
- 3. A composition in accordance with claim 1, wherein said carrier is formulated for local application.
- 4. A composition in accordance with claim 1, wherein said second agent is selected from the group consisting of phosphodiesterase type II inhibitors phosphodiesterase type IV inhibitors, phosphodiesterase type V inhibitors, and nonspecific phosphodiesterase inhibitors.
- 5. A composition in accordance with claim 1, wherein said second agent is selected from the group consisting of β-adrenergic agonists.
- 6. A composition in accordance with claim 5, wherein said β-adrenergic agonist is selected from the group consisting of β2-adrenergic agonists and β3-adrenergic agonists.
- 7. A composition in accordance with claim 1, wherein said second agent is selected from the group consisting of ATP-sensitive K+ channel activators.
- 8. A composition for the treatment of an anorectal disorder, and for controlling the pain associated therewith, said composition comprising a phosphodiesterase inhibitor and a pharmaceutically acceptable carrier.
- 9. A composition in accordance with claim 8, wherein said phosphodiesterase inhibitor is selected from the group consisting of phosphodiesterase type II inhibitors, phosphodiesterase type IV inhibitors, phosphodiesterase type V inhibitors, and nonspecific phosphodiesterase inhibitors.
- 10. A composition in accordance with claim 9, further comprising an agent selected from the group consisting of β-adrenergic agonists, cAMP-dependent protein kinase activators, α1-adrenergic antagonists, L-type Ca2+ channel blockers, estrogens, ATP-sensitive K+ channel activators and smooth muscle relaxants.
- 11. A composition for the treatment of an anorectal disorder, and for controlling the pain associated therewith, said composition comprising a β-adrenergic agonist and a pharmaceutically acceptable carrier.
- 12. A composition in accordance with claim 11, wherein said β-adrenergic agonist is specific for a receptor isoform selected from the group consisting of β2, β3 and combinations thereof.
- 13. A composition in accordance with claim 11, wherein said β-adrenergic agonist is isoproterenol.
- 14. A composition in accordance with claim 11, further comprising an agent selected from the group consisting of cAMP-hydrolyzing PDE inhibitors, nonspecific PDE inhibitors, α1-adrenergic antagonists, estrogens, L-type Ca2+ channel blockers, ATP-sensitive K+ channel activators and smooth muscle relaxants.
- 15. A composition for the treatment of an anorectal disorder, and for controlling the pain associated therewith, said composition comprising an ATP-sensitive K+ channel activator and a pharmaceutically acceptable carrier.
- 16. A composition in accordance with claim 15, further comprising an agent selected from the group consisting of cAMP-dependent protein kinase activators, estrogens, α1-adrenergic antagonists, L-type Ca2+ channel blockers and smooth muscle relaxants.
- 17. A composition for the treatment of an anorectal disorder, and for controlling the pain associated therewith, said composition comprising an α1-adrenergic antagonist and a pharmaceutically acceptable carrier.
- 18. A composition in accordance with claim 17, said composition further comprising an agent selected from the group consisting of cAMP-hydrolyzing phosphodiesterase inhibitors, estrogens and smooth muscle relaxants.
- 19. A composition in accordance with claim 17, wherein said cAMP-hydrolyzing phosphodiesterase inhibitor is a phosphodiesterase type IV inhibitor.
- 20. A composition for the treatment of an anorectal disorder, and for controlling the pain associated therewith said composition comprising a cAMP-dependent protein kinase activator and an L-type Ca2+ channel blocker.
- 21. A composition for the treatment of an anorectal disorder, and for controlling the pain associated therewith, said composition comprising a cGMP-dependent protein kinase activator and a pharmaceutically acceptable carrier.
- 22. A composition for the treatment of an anorectal disorder, and for controlling the pain associated therewith, said composition comprising a nonspecific cyclic nucleotide-dependent protein kinase activator, optionally in admixture with a smooth muscle relaxant.
- 23. A method of treating an anorectal disorder, and for controlling the pain associated therewith, the method comprising administering to a subject in need of such treatment a therapeutically effective amounts of a NO donor and a second agent selected from the group consisting of phosphodiesterase type II inhibitors, phosphodiesterase type IV inhibitors, phosphodiesterase type V inhibitors, nonspecific phosphodiesterase inhibitors, superoxide scavengers, β-adrenergic agonists, cAMP-dependent protein kinase activators, α1-adrenergic antagonists, estrogens, L-type Ca2+ channel blockers, ATP-sensitive K+ channel activators and smooth muscle relaxants.
- 24. A method in accordance with claim 23, wherein said NO donor and said second agent are administered in combination.
- 25. A method in accordance with claim 23, wherein said second agent is administered prior to said NO donor.
- 26. A method in accordance with claim 23, wherein said anorectal disorder is an anal fissure.
- 27. A method of treating an anorectal disorder, and for controlling the pain associated therewith, the method comprising administering to a subject in need of such treatment a therapeutically effective amount of a composition comprising a phosphodiesterase inhibitor.
- 28. A method in accordance with claim 27, further comprising administering to said subject a second agent selected from the group consisting of β-adrenergic agonists, cAMP-dependent protein kinase activators, α1-adrenergic antagonists, estrogens, L-type Ca2+ channel blockers, ATP-sensitive K+ channel activators and smooth muscle relaxants.
- 29. A method of treating an anorectal disorder, and for controlling the pain associated therewith, the method comprising administering to a subject in need of such treatment a therapeutically effective amount of a composition comprising a β-adrenergic agonist.
- 30. A method in accordance with claim 29, further comprising administering to said subject a second agent selected from the group consisting of cAMP-dependent protein kinase activators, α1-adrenergic antagonists, estrogens, L-type Ca2+ channel blockers, ATP-sensitive K+ channel activators and smooth muscle relaxants.
- 31. A method of treating an anorectal disorder, and for controlling the pain associated therewith, the method comprising administering to a subject in need of such treatment a therapeutically effective amount of a composition comprising an ATP-sensitive potassium channel opener and an agent that promotes cAMP-mediated anal sphincter relaxation.
- 32. A method of treating an anorectal disorder, and for controlling the pain associated therewith, the method comprising administering to a subject in need of such treatment a therapeutically effective amount of a composition comprising a potassium channel opener, wherein said therapeutically effective amount decreases hypertonicity of an anal sphincter muscle of the subject.
- 33. A method of treating an anorectal disorder, and for controlling the pain associated therewith, the method comprising administering to a subject in need of such treatment a therapeutically effective amount of a composition comprising a pharmaceutically acceptable carrier and an agent which increases a level of cyclic guanidine monophosphate or cyclic adenosine monophosphate in a tissue of an anal sphincter muscle of the subject, thereby decreasing hypertonicity of the anal sphincter muscle of the subject.
CROSS-REFERENCES TO RELATED APPLICATIONS
[0001] This application claims priority from U.S. Provisional Application Nos. 60/112,325, filed Dec. 14, 1998; 60/139,916, filed Jun. 17, 1999 and 60/155,318, filed Sep. 21, 1999. The disclosures of each are incorporated herein by reference in their entirety.
Provisional Applications (3)
|
Number |
Date |
Country |
|
60112325 |
Dec 1998 |
US |
|
60139916 |
Jun 1999 |
US |
|
60155318 |
Sep 1999 |
US |
Continuations (1)
|
Number |
Date |
Country |
Parent |
09460306 |
Dec 1999 |
US |
Child |
09769621 |
Jan 2001 |
US |